Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.1900 (-2.09%) ($12.1300 - $12.6700) on Thu. May. 28, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.14% (three month average) | RSI | 57 | Latest Price | $12.1900(-2.09%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.7% a day on average for past five trading days. | Weekly Trend | FOLD advances 2.4% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(54%) IWO(50%) XBI(50%) IWM(46%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -3.57% in a week (0% probabilities). VIXM(-28%) VXX(-15%) UUP(-11%) UNG(-5%) TLT(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.57% (StdDev 7.14%) | Hourly BBV | 0 () | Intraday Trend | -3.3% | | | |
|
5 Day Moving Average | $12.4(-1.69%) | 10 Day Moving Average | $12.24(-0.41%) | 20 Day Moving Average | $12.02(1.41%) | To recent high | -4.9% | To recent low | 83.9% | Market Cap | $3.148b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |